A61K 2039/585
Wherein the target is cancer
Official title: {wherein the target is cancer}
A61K2039/585 (Wherein the target is cancer) appears on 1,039 US grants and 1,886 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,039
- Published applications
- 1,886
- Assignees
- 788
- Inventors
- 2,786
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 2 |
| 2002 | 2 | 6 |
| 2003 | 4 | 6 |
| 2004 | 1 | 10 |
| 2005 | 3 | 12 |
| 2006 | 6 | 11 |
| 2007 | 5 | 14 |
| 2008 | 5 | 19 |
| 2009 | 5 | 19 |
| 2010 | 6 | 29 |
| 2011 | 10 | 22 |
| 2012 | 11 | 31 |
| 2013 | 11 | 31 |
| 2014 | 21 | 40 |
| 2015 | 35 | 83 |
| 2016 | 41 | 96 |
| 2017 | 52 | 103 |
| 2018 | 85 | 148 |
| 2019 | 90 | 153 |
| 2020 | 117 | 190 |
| 2021 | 133 | 208 |
| 2022 | 99 | 161 |
| 2023 | 85 | 170 |
| 2024 | 97 | 160 |
| 2025 | 60 | 99 |
| 2026 | 46 | 63 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Immunomodulatory and oncolytic minicells and methods of use22 Sep 2026US 12,741,010 B2Vaxiion Therapeutics, Inc.
- Intracellular delivery of biomolecules to modify immune response8 Sep 2026US 12,728,163 B2Stemcell Technologies Canada Inc.
- Methods of preparing anti-human papillomavirus antigen T cells11 Aug 2026US 12,702,706 B2The United States of America, as represented by the Secretary, Department of Health and Human Seervices
- Cell capable of activating immune system, and pharmaceutical composition containing said cell11 Aug 2026US 12,703,867 B2Riken
- Treatment using oncolytic virus21 Jul 2026US 12,685,767 B2Replimune Limited
- Improved expression of surface-displayed antigens1 Oct 2026US 2026/0295030 A1Inprother Aps
- Use of inhibitors of adam12 as adjuvants in tumor therapies24 Sep 2026US 2026/0286009 A1Institut National de la Sante et de la Recherche Medicale
- Nucleic acid vaccine for activating nkg2c+ natural killer cells24 Sep 2026US 2026/0286356 A1Charite-Universitatsmedizin Berlin
- Method of vaccinating for cancer and device and kit therefor17 Sep 2026US 2026/0273046 A1Purdue Research Foundation
- Adenoviral vector vaccine, and preparation method and use thereof10 Sep 2026US 2026/0265702 A1Cansino Biologics Inc.
Most cited
By later US patents
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Methods for treatment of cancer216US 8,916,381 B1The Trustees of the University of Pennyslvania · 2014
- Compositions for treatment of cancer199US 8,975,071 B1The Trustees of the University of Pennsylvania · 2015
- Methods for treatment of cancer199US 9,101,584 B2The Trustees of the University of Pennsylvania · 2015